Genmab AS Stock

Genmab AS Stock-Based Compensation

The Stock-Based Compensation (SBC) of Genmab AS (GMAB) as of Aug 15, 2026 is 128.00 M USD. In the previous year, Stock-Based Compensation (SBC) was 721.00 M USD — a change of -82.25% (lower).

Stock-Based Compensation

128.00 MUSD

YoY

-82.25%

Last updated:

Stock-Based Compensation (SBC) of Genmab AS is 2026 128.00 M USD. Stock-Based Compensation (SBC) of Genmab AS was 2025 721.00 M USD. It decreases by -82.25% lower compared to the previous year.
Access this data via the Eulerpool API

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Stock-Based Compensation (SBC) of Genmab AS is 128.00 M USD in 2026.

Stock-Based Compensation (SBC) of Genmab AS changed from 721.00 M USD to 128.00 M USD, representing a -82.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Genmab AS historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Genmab AS

All Key Metrics — Genmab AS